WILMINGTON, N.C.--(BUSINESS WIRE)--The lead product for CardioPharma, a patented triple-combination once-daily Cardiovascular Disease (CVD) capsule, has successfully completed the FDA required pharmacokinetic study. “This study clearly demonstrates the lead product for CardioPharma is a reality and a few shorts steps from NDA filing. The outstanding results of our pharmacokinetic study, coupled with demonstrable product stability data and commercial scale up abilities, set the stage for our upcoming pharmacodynamic study,” stated Don Sellers, CardioPharma Chairman and CEO. The planned pharmacodynamic study and characterization of food effects for labeling are the last studies for CardioPharma’s lead product prior to NDA submission.
Help employers find you! Check out all the jobs and post your resume.
